CVS picks Amgen's Repatha

CVS Health Corp. (NYSE:CVS) has selected Repatha evolocumab from Amgen Inc. (NASDAQ:AMGN) as its exclusive PCSK9 inhibitor in exchange for undisclosed discounts on the lipid-lowering mAb.

"We have determined that choosing a single PCSK9 inhibitor for our commercial formularies allows us to get the best price possible for clients and preserves our commitment to deliver the best care available," CMO Troyen Brennan said in a statement. ...